» Articles » PMID: 38461852

The Ketone Bridge Between the Heart and the Bladder: How Fast Should We Go?

Overview
Journal Int Neurourol J
Date 2024 Mar 10
PMID 38461852
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolic syndrome (MS) is associated with both cardiovascular and bladder dysfunction. Insulin resistance (IR) and central obesity, in particular, are the main risk factors. In these patients, vicious pathological cycles exacerbate abnormal carbohydrate metabolism and sustain an inflammatory state, with serious implications for both the heart and bladder. Ketone bodies serve as an alternative energy source in this context. They are considered a "super-fuel" because they generate adenosine triphosphate with less oxygen consumption per molecule, thus enhancing metabolic efficiency. Ketone bodies have a positive impact on all components of MS. They aid in weight loss and glycemic control, lower blood pressure, improve lipid profiles, and enhance endothelial function. Additionally, they possess direct anti-inflammatory, antioxidant, and vasodilatory properties. A shared key player in dysfunction of both the heart and bladder dysfunction is the formation of the NLRP3 inflammasome, which ketone bodies inhibit. Interventions that elevate ketone body levels-such as fasting, a ketogenic diet, ketone supplements, and sodium-glucose cotransporter 2 inhibitors-have been shown to directly affect cardiovascular outcomes and improve lower urinary tract symptoms derived from MS. This review explores the pathophysiological basis of the benefits of ketone bodies in cardiac and bladder dysfunction.

Citing Articles

Editorial for 'Lower Urinary Tract Symptoms: Clinical and Translational Science'.

Birder L Int Neurourol J. 2024; 28(Suppl 1):1.

PMID: 38461851 PMC: 10932573. DOI: 10.5213/inj.2424edi01.

References
1.
Sun Y, Chen H, Bai Y, Zhang T, Bai W, Jiang B . Ketogenic diet may be a new approach to treatment stress urinary incontinence in obese elderly women: report of five cases. BMC Womens Health. 2022; 22(1):402. PMC: 9533581. DOI: 10.1186/s12905-022-01987-5. View

2.
Luda K, Longo J, Kitchen-Goosen S, Duimstra L, Ma E, Watson M . Ketolysis drives CD8 T cell effector function through effects on histone acetylation. Immunity. 2023; 56(9):2021-2035.e8. PMC: 10528215. DOI: 10.1016/j.immuni.2023.07.002. View

3.
Penson D, Munro H, Signorello L, Blot W, Fowke J . Obesity, physical activity and lower urinary tract symptoms: results from the Southern Community Cohort Study. J Urol. 2011; 186(6):2316-22. PMC: 3327364. DOI: 10.1016/j.juro.2011.07.067. View

4.
Yurista S, Chong C, Badimon J, Kelly D, de Boer R, Westenbrink B . Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021; 77(13):1660-1669. DOI: 10.1016/j.jacc.2020.12.065. View

5.
Ansary T, Nakano D, Nishiyama A . Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System. Int J Mol Sci. 2019; 20(3). PMC: 6387046. DOI: 10.3390/ijms20030629. View